Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 14 studies | 29% ± 11% | |
| oligodendrocyte precursor cell | 13 studies | 39% ± 18% | |
| astrocyte | 12 studies | 40% ± 19% | |
| microglial cell | 11 studies | 28% ± 11% | |
| fibroblast | 11 studies | 27% ± 8% | |
| oligodendrocyte | 10 studies | 36% ± 11% | |
| GABAergic neuron | 9 studies | 45% ± 21% | |
| glutamatergic neuron | 9 studies | 43% ± 25% | |
| adipocyte | 9 studies | 35% ± 10% | |
| smooth muscle cell | 9 studies | 27% ± 7% | |
| epithelial cell | 8 studies | 29% ± 14% | |
| macrophage | 8 studies | 28% ± 9% | |
| interneuron | 6 studies | 49% ± 21% | |
| cardiac muscle cell | 6 studies | 48% ± 17% | |
| endothelial cell of lymphatic vessel | 6 studies | 28% ± 6% | |
| pericyte | 6 studies | 24% ± 9% | |
| neuron | 5 studies | 47% ± 14% | |
| ciliated cell | 5 studies | 24% ± 4% | |
| type I pneumocyte | 5 studies | 21% ± 5% | |
| basal cell | 5 studies | 32% ± 15% | |
| retinal ganglion cell | 4 studies | 30% ± 10% | |
| retina horizontal cell | 4 studies | 24% ± 4% | |
| retinal cone cell | 4 studies | 22% ± 2% | |
| Mueller cell | 4 studies | 25% ± 3% | |
| hepatocyte | 4 studies | 54% ± 15% | |
| type II pneumocyte | 4 studies | 19% ± 3% | |
| connective tissue cell | 4 studies | 17% ± 1% | |
| monocyte | 4 studies | 19% ± 3% | |
| goblet cell | 4 studies | 26% ± 13% | |
| mast cell | 4 studies | 18% ± 2% | |
| GABAergic interneuron | 3 studies | 26% ± 6% | |
| glial cell | 3 studies | 23% ± 5% | |
| granule cell | 3 studies | 25% ± 3% | |
| plasma cell | 3 studies | 24% ± 6% | |
| amacrine cell | 3 studies | 19% ± 2% | |
| glycinergic amacrine cell | 3 studies | 20% ± 4% | |
| myeloid cell | 3 studies | 20% ± 5% | |
| endothelial cell of vascular tree | 3 studies | 25% ± 9% | |
| ependymal cell | 3 studies | 38% ± 15% | |
| club cell | 3 studies | 28% ± 7% | |
| renal principal cell | 3 studies | 22% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1177.19 | 1445 / 1445 | 100% | 11.51 | 183 / 183 |
| prostate | 100% | 1454.04 | 245 / 245 | 100% | 25.40 | 502 / 502 |
| thymus | 100% | 2109.42 | 653 / 653 | 100% | 22.14 | 604 / 605 |
| breast | 100% | 1541.79 | 459 / 459 | 100% | 22.01 | 1116 / 1118 |
| brain | 100% | 1518.27 | 2641 / 2642 | 100% | 26.29 | 704 / 705 |
| kidney | 100% | 1920.83 | 89 / 89 | 100% | 17.43 | 899 / 901 |
| adrenal gland | 100% | 1747.62 | 258 / 258 | 100% | 18.24 | 229 / 230 |
| bladder | 100% | 1396.24 | 21 / 21 | 99% | 13.99 | 499 / 504 |
| pancreas | 99% | 932.47 | 326 / 328 | 99% | 12.34 | 177 / 178 |
| lung | 99% | 1009.31 | 573 / 578 | 100% | 11.75 | 1151 / 1155 |
| liver | 100% | 2531.56 | 226 / 226 | 99% | 16.74 | 401 / 406 |
| uterus | 100% | 1577.64 | 170 / 170 | 98% | 12.09 | 452 / 459 |
| intestine | 100% | 1449.47 | 966 / 966 | 98% | 12.73 | 517 / 527 |
| stomach | 100% | 999.83 | 358 / 359 | 98% | 12.15 | 280 / 286 |
| ovary | 100% | 1690.75 | 180 / 180 | 96% | 8.63 | 414 / 430 |
| skin | 100% | 1465.23 | 1809 / 1809 | 94% | 13.66 | 444 / 472 |
| adipose | 100% | 1277.56 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 14.91 | 29 / 29 |
| muscle | 100% | 1162.69 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1429.63 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 12.26 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 16.68 | 1 / 1 |
| blood vessel | 100% | 1062.15 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 1147.78 | 844 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 93% | 11.75 | 74 / 80 |
| peripheral blood | 70% | 733.91 | 650 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0044597 | Biological process | daunorubicin metabolic process |
| GO_0006633 | Biological process | fatty acid biosynthetic process |
| GO_0044598 | Biological process | doxorubicin metabolic process |
| GO_0051290 | Biological process | protein heterotetramerization |
| GO_0051289 | Biological process | protein homotetramerization |
| GO_1990204 | Cellular component | oxidoreductase complex |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0004316 | Molecular function | 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity |
| GO_0008753 | Molecular function | NADPH dehydrogenase (quinone) activity |
| GO_0070402 | Molecular function | NADPH binding |
| GO_0003955 | Molecular function | NAD(P)H dehydrogenase (quinone) activity |
| GO_0048038 | Molecular function | quinone binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0016616 | Molecular function | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor |
| Gene name | CBR4 |
| Protein name | 3-ketoacyl-[acyl-carrier-protein] reductase beta subunit (Quinone reductase CBR4) Carbonyl reductase 4 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100) (3-ketoacyl-[acyl-carrier-protein] reductase beta subunit) (KAR beta subunit) (Carbonyl reductase family member 4) (CBR4) (Quinone reductase CBR4) (EC 1.6.5.10) (Short chain dehydrogenase/reductase family 45C member 1) |
| Synonyms | SDR45C1 |
| Description | FUNCTION: Component of the heterotetramer complex KAR (3-ketoacyl-[acyl carrier protein] reductase or 3-ketoacyl-[ACP] reductase) that forms part of the mitochondrial fatty acid synthase (mtFAS). Beta-subunit of the KAR heterotetramer complex, responsible for the 3-ketoacyl-ACP reductase activity of the mtFAS, reduces 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP] in a NADPH-dependent manner with no chain length preference, thereby participating in mitochondrial fatty acid biosynthesis . The homotetramer has NADPH-dependent quinone reductase activity (in vitro), hence could play a role in protection against cytotoxicity of exogenous quinones . As a heterotetramer, it can also reduce 9,10-phenanthrenequinone, 1,4-benzoquinone and various other o-quinones and p-quinones (in vitro) . . |
| Accessions | ENST00000504561.1 ENST00000306193.8 [Q8N4T8-1] ENST00000506808.1 D6RAV8 H0Y962 D6RJF4 ENST00000507752.1 Q8N4T8 ENST00000504480.5 [Q8N4T8-2] ENST00000510042.5 D6RGF2 |